The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

FCE-22101     sodium(5R,6R)-3- (aminocarbonyloxymethyl)...

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ritipenem


High impact information on Ritipenem


Chemical compound and disease context of Ritipenem


Biological context of Ritipenem


Anatomical context of Ritipenem

  • The average amount of FCE 22101 excreted in urine and feces corresponded to 9.0 and 1.6% of the dose, respectively [5].
  • When the classical competitive procedure was modified by increasing the time of incubation of either membranes or growing cells with FCE 22101, the antibiotic showed a much higher affinity for penicillin-binding protein 2a and saturated the protein at a concentration close to the MIC, with slow kinetics [1].
  • Dose finding study on the efficacy and safety of ritipenem in complicated urinary tract infections [13].

Associations of Ritipenem with other chemical compounds


Gene context of Ritipenem

  • FCE 22891 is the oral prodrug of FCE 22101, a new broad-spectrum penem [19].
  • The activity of the antibiotics against beta-lactamase-producing strains was also tested and here FCE 22101 exhibited the greatest inhibitory effect on bacterial growth [18].
  • The pneumococcal strains included lyt- mutants in which the autolysin gene was inactivated or deleted and clinical isolates with penicillin MIC greater than 1.0 mg/l. The killing activity of FCE 22101 was superior to that of penicillin for all strains [20].
  • High-performance liquid chromatographic methods for the determination of the penems SCH 29482 and FCE 22101 in human serum and urine [21].
  • Chromatographic separation of FCE 22101 was achieved using an SP8700 solvent delivery system (Spectra-Physics), an SP8780XR autosampler (Spectra-Physics) and a reverse-phase C18 mu-BondaPak column (8 X 100 mm) radially compressed in a Z module (Millipore, UK) [22].

Analytical, diagnostic and therapeutic context of Ritipenem

  • Urine samples obtained at timed intervals were assayed for FCE 22101 and its metabolites P1 and P2 by HPLC [23].
  • Plasma and urine concentrations of FCE 22101, and in the cross-over study also its open ring metabolites P1 and P2, were determined by HPLC [24].
  • The 24 h urinary recoveries of the parent drug and its metabolites were similar after treatments A and B. Mean recoveries +/- S.D were 29 +/- 13% (FCE 22101), 31 +/- 12% (P1) and 7 +/- 2% (P2) of the dose [23].
  • The urinary recovery and tolerability of FCE 22101, a broad spectrum injectable penem, were investigated in a multicentre single-blind randomized crossover study of 60 healthy male volunteers [23].
  • A high performance liquid chromatography method for the determination of FCE 22101, a novel penem antimicrobial, in serum [22].


  1. Interaction of FCE 22101 with penicillin-binding proteins of Staphylococcus aureus. Tonin, E.A., Fontana, R. Antimicrob. Agents Chemother. (1989) [Pubmed]
  2. Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics. Wise, R., Andrews, J.M., Danks, G. Antimicrob. Agents Chemother. (1983) [Pubmed]
  3. Potent bacteriolytic activity of ritipenem associated with a characteristic profile of affinities for penicillin-binding proteins of Haemophilus influenzae. Inui, T., Oshida, T., Endo, T., Matsushita, T. Antimicrob. Agents Chemother. (1999) [Pubmed]
  4. Pseudomonas aeruginosa reveals high intrinsic resistance to penem antibiotics: penem resistance mechanisms and their interplay. Okamoto, K., Gotoh, N., Nishino, T. Antimicrob. Agents Chemother. (2001) [Pubmed]
  5. Pharmacokinetics of [14C]FCE 22891, a penem antibiotic, following oral administration to healthy volunteers. Efthymiopoulos, C., Strolin Benedetti, M., Sassella, D., Boobis, A., Davies, D. Antimicrob. Agents Chemother. (1992) [Pubmed]
  6. In vitro activity of L-627, a new carbapenem. Catchpole, C.R., Wise, R., Thornber, D., Andrews, J.M. Antimicrob. Agents Chemother. (1992) [Pubmed]
  7. Biochemical characterization of a beta-lactamase that hydrolyzes penems and carbapenems from two Serratia marcescens isolates. Yang, Y.J., Wu, P.J., Livermore, D.M. Antimicrob. Agents Chemother. (1990) [Pubmed]
  8. In-vitro activity of FCE 22101 and synergy studies with other antimicrobial agents. Chin, N.X., Neu, H.C. J. Antimicrob. Chemother. (1989) [Pubmed]
  9. The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics. Neu, H.C., Chin, N.X., Labthavikul, P. J. Antimicrob. Chemother. (1985) [Pubmed]
  10. A study of the pharmacokinetics and tolerability of ritipenem acoxil in healthy volunteers following multiple oral dosing. Poggesi, I., Spinelli, R., Frigerio, E., Strolin Benedetti, M., Carra, L., Sassella, D., Rimoldi, R. J. Antimicrob. Chemother. (1997) [Pubmed]
  11. Pharmacokinetics and metabolism of FCE 22101 following its administration as the oral pro-drug FCE 22891. Lovering, A.M., MacGowan, A.P., Lewis, D.A., Reeves, D.S. J. Antimicrob. Chemother. (1992) [Pubmed]
  12. Rapid hydrolysis in vivo in man of FCE 22891, the orally absorbed ester of FCE 22101. Vinçon, G., Albin, H., Battaglia, R., Mignon, A., Strolin Benedetti, M. J. Antimicrob. Chemother. (1990) [Pubmed]
  13. Dose finding study on the efficacy and safety of ritipenem in complicated urinary tract infections. Bischoff, W., Herceg, R., Sassella, D., Landi, V., Castellani, P. Journal of chemotherapy (Florence, Italy) (1995) [Pubmed]
  14. In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem. Van der Auwera, P., Ernst, F., Grenier, P., Glupczynski, Y., Husson, M., Klastersky, J. J. Antimicrob. Chemother. (1987) [Pubmed]
  15. Efficacy of FCE 22101 compared with imipenem and with gentamicin plus metronidazole in the treatment of experimental intra-abdominal infections in rats. Nord, C.E., Lahnborg, G. J. Antimicrob. Chemother. (1989) [Pubmed]
  16. Synthesis and antimicrobial spectrum of FCE 22101 and its orally available ester FCE 22891. Franceschi, G., Perrone, E., Alpegiani, M., Bedeschi, A., Battistini, C., Zarini, F., Della Bruna, C. J. Antimicrob. Chemother. (1989) [Pubmed]
  17. Pharmacokinetics in healthy subjects of FCE 22101 and its acetoxymethyl ester, FCE 22891: effect of co-administration of imipenem/cilastatin on the renal metabolism of FCE 22101. Norrby, S.R., Burman, L.A., Sassella, D., Corigli, R., Cassinelli, G., Franceschi, G., Dornbusch, K. J. Antimicrob. Chemother. (1990) [Pubmed]
  18. Activity of FCE 22101 and other beta-lactam antibiotics against experimental genital infections in the rat and mouse. Castellani, P., Meinardi, G., Della Bruna, C. J. Antimicrob. Chemother. (1989) [Pubmed]
  19. Pharmacokinetics of FCE 22891, a new oral penem. Saathoff, A., Lode, H., Hampel, B., Deppermann, K.M., Borner, K., Koeppe, P. Antimicrob. Agents Chemother. (1990) [Pubmed]
  20. Lytic and bactericidal activity of FCE 22101. Jabes, D., Tomasz, A. J. Antimicrob. Chemother. (1989) [Pubmed]
  21. High-performance liquid chromatographic methods for the determination of the penems SCH 29482 and FCE 22101 in human serum and urine. Méndez, R., Negro, A., Martín-Villacorta, J. J. Chromatogr. (1992) [Pubmed]
  22. A high performance liquid chromatography method for the determination of FCE 22101, a novel penem antimicrobial, in serum. Baskerville, A.J., Felmingham, D., Grüneberg, R.N. Drugs under experimental and clinical research. (1988) [Pubmed]
  23. Urinary recovery and tolerability of FCE 22101 following single intravenous administration under restricted and high fluid intake. Sassella, D., Cassinelli, G., Corigli, R., Dewland, P., Hutt, V., Lode, H., Ballard, R.C. J. Antimicrob. Chemother. (1989) [Pubmed]
  24. Pharmacokinetics of FCE 22101 in man following different modes of administration. Lovering, A.M., White, L.O., Lewis, D.A., MacGowan, A.P., Routh, K.R., Pickin, D.M., Reeves, D.S. J. Antimicrob. Chemother. (1989) [Pubmed]
WikiGenes - Universities